Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML

Optimal treatment of acute myeloid leukemia (AML) arising in elderly patients remains a challenge. FDA approval of Ivosidenib and Enasidenib, small molecule inhibitors of isocitrate dehydrogenase enzymes (IDH1 and 2) have opened new avenues of treatment. We present a 60-year-old woman with refractor...

Full description

Saved in:
Bibliographic Details
Published in:Exp Hematol Oncol
Main Authors: Jasra, Sakshi, Kazemi, Mohammed, Shah, Nishi, Chen, Jiahao, Fehn, Karen, Wang, Yanhua, Mantzaris, Ioannis, Kornblum, Noah, Sica, Alejandro, Bachier, LizaMarie, Goldfinger, Mendel, Gritsman, Kira, Braunschweig, Ira, Steidl, Ulrich, Shastri, Aditi, Verma, Amit
Format: Artigo
Language:Inglês
Published: BioMed Central 2021
Subjects:
Letter to the Editor
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7784272/
https://ncbi.nlm.nih.gov/pubmed/33397455
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-020-00186-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items